San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Biotheryx is raising $100,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Jaime Donadio played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biotheryx

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments intended to extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, as well as PHM ‘molecular glues’, that enable the design of small molecules to regulate protein equilibrium. This technology is designed to utilize the body’s own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered ‘undruggable’.

To learn more about Biotheryx, visit http://biotheryx.com/

Contact:
Jaime Donadio, Chief Financial Officer
858-550-6000
https://www.linkedin.com/in/jamiedonadio/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved